Santini Francesco, Casali Gianluca, Franchi Gianluigi, Auriemma Stefano, Lusini Mario, Barozzi Luca, Favaro Alessandro, Messina Antonio, Mazzucco Alessandro
Division of Cardiac Surgery and Anesthesiology, University of Verona, OCM Borgo Trento, Piazzale Stefani 1, 37126, Verona, Italy.
Int J Cardiol. 2005 Aug 18;103(2):156-63. doi: 10.1016/j.ijcard.2004.08.050.
Inhaled nitric oxide (iNO) is proposed in the management of pulmonary hypertension (PH) in patients undergoing cardiac surgery. Secondary PH related to a long-standing heart valve disease however may be refractory to iNO. Aim of this prospective study was to determine whether the combination of iNO plus dipyridamole (DP), a cyclic guanosine monophosphate-specific phosphodiesterase inhibitor (PDE5), may enhance and/or prolong the response to iNO in adult patients with secondary valve-related PH undergoing cardiac surgery, and attenuate rebound events related to its discontinuation.
Responses in 27 patients, 11 male, mean age 72+/-11 years, with PH due to mitral and/or aortic valve disease, were studied in the Intensive Care Unit after cardiac surgery, during sedation and stable hemodynamic conditions. The effect of isolated iNO administration (40 ppm), iNO combined with DP (0.2 mg/kg i.v.), and DP alone (1 mg/kg/24 h) on pulmonary vascular resistance, mean pulmonary artery pressure, cardiac index, mixed venous O2Sat%, and mean arterial pressure were determined.
All patients showed at least a 10% decrease in pulmonary vascular resistance vs. baseline after administration of iNO [responders]. Inhaled NO and the combination of iNO/DP produced a reduction of pulmonary vascular resistance and mean pulmonary artery pressure (p<0.05). Cardiac index improved with a significant difference between iNO and the association iNO/DP versus baseline (p<0.05). This significant hemodynamic improvement versus baseline was maintained during isolated DP administration (p<0.05), but not during isolated iNO discontinuation. Mixed venous oxygen saturation showed an overall improvement of 17% (p<0.05).
Inhaled NO and DP infusion might represent a valuable association in the management of PH secondary to a heart valve disease in patients undergoing cardiac surgery. Their beneficial hemodynamic effects might be particularly valuable in the management of patients with associated right ventricular dysfunction.
吸入一氧化氮(iNO)被推荐用于心脏手术患者肺动脉高压(PH)的治疗。然而,与长期心脏瓣膜病相关的继发性PH可能对iNO治疗无效。本前瞻性研究的目的是确定iNO联合双嘧达莫(DP,一种环磷酸鸟苷特异性磷酸二酯酶抑制剂(PDE5))是否能增强和/或延长iNO对接受心脏手术的继发瓣膜相关PH成年患者的反应,并减轻与iNO停用相关的反跳事件。
对27例患者(11例男性,平均年龄72±11岁)进行研究,这些患者因二尖瓣和/或主动脉瓣疾病导致PH,在心脏手术后入住重症监护病房,处于镇静状态且血流动力学稳定。测定单独吸入iNO(40 ppm)、iNO联合DP(0.2 mg/kg静脉注射)以及单独使用DP(1 mg/kg/24 h)对肺血管阻力、平均肺动脉压、心脏指数、混合静脉血氧饱和度和平均动脉压的影响。
所有患者吸入iNO后与基线相比肺血管阻力至少降低了10%[反应者]。吸入NO和iNO/DP联合用药可降低肺血管阻力和平均肺动脉压(p<0.05)。心脏指数改善,iNO与iNO/DP联合用药与基线相比有显著差异(p<0.05)。单独使用DP期间,与基线相比这种显著的血流动力学改善得以维持(p<0.05),但单独停用iNO期间则不然。混合静脉血氧饱和度总体提高了17%(p<0.05)。
吸入NO和输注DP可能是心脏手术患者继发于心脏瓣膜病的PH治疗中的一种有价值的联合用药方式。它们有益的血流动力学效应在伴有右心室功能障碍患者的治疗中可能特别有价值。